TruSight Oncology 500 is a next-generation sequencing tumor profiling assay that analyzes 523 genes for cancer-related biomarkers and supports the identification of DNA and RNA variants implicated in various tumor types, including measuring key immunotherapy biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI). This provides an overview of TruSight Oncology 500 analysis and is targeted at new users of the TruSight Oncology 500 workflow. We cover the following topics: overview of the TruSight Oncology 500 analysis workflow; how to assess biomarker (TMB and MSI) results; options for data analysis and variant interpretation. View upcoming Support Webinars https://support.illumina.com/training.html Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM